Cellectar Biosciences, Inc. Resources
Patients
News & Media
Investors
Contact
Cellectar Biosciences, Inc.
Home
About
Overview
Partnerships
Management Team
Board of Directors
Platform
Overview
Posters & Publications
Product Pipeline
Overview
Iopofosine
Clinical Studies
Overview
Waldenstrom’s Macroglobulinemia Phase 2 Study
Active, not recruiting
Relapsed or Refractory Select B-Cell Malignancies Clinical Study
Active, not recruiting
Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG
Active, not recruiting
Patients
News & Media
Investors
Contact
Contact
Clinical Studies
Clinical Studies
Overview
Waldenstrom’s Macroglobulinemia Phase 2 Study
Relapsed or Refractory Select B-Cell Malignancies Clinical Study
Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG
Contact us for more information on the iopofosine Clinical Studies
Name
Email
I am a:
Patient
Friend, Family, Caregiver
Physician/Healthcare Provider
Clinical Trial
Select Your Trial
Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia
Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG
Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia
Message
This site is protected by hCaptcha and its
Privacy Policy
and
Terms of Service
apply.
Submit